Prohost BiotechResearch Platform

Home Articles Trick or TradeThe First Post in the Series About "Treating Neurodegenerative Diseases"

Trick or Trade

Premium

The First Post in the Series About "Treating Neurodegenerative Diseases"

Treating Neurodegenerative Disease Our priority at Prohost now is posting a series of articles about Biotech firms whose pipelines are comprised of novel products aimed at treating devastating and lif...

P

Prohost Biotech

March 17, 2023

1 min read

20

0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles

Expert analysis

Research reports

Tags

Biogen Inc (BIIB)

Ionis Pharmaceuticals Inc (IONS)

Comments (0)

Please sign in to join the discussion

Related Articles

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

BioNTech BioNTech ( BNTX ) announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in patients with HER2-expressing, advanced endometrial cancer whos...

Prohost Biotech

Apr 17, 2026

Zymeworks Inc Question and Answer

Zymeworks Inc Q & A Q: What’s the story about Zymeworks entering into a deal with Royalty Pharma? A: Zymeworks and Royalty Pharma have already entered into $250 Million Royalty-Backed Note Financing....

Prohost Biotech

Mar 12, 2026

Milestone Receives FDA Approval of CARDAMYST™ as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia

Milestone in the NEWS MONTREAL and CHARLOTTE, Milestone ® ( MIST ) announced that the U.S. FDA approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for...

Prohost Biotech

Dec 16, 2025